Dr Geethanjali Gude

Disease detective 🧐
PGY-1
@UTSW_Pathology
PGIMER Alumni

[Kiril_T_Can @Kiril_T_Can]

New in Virchows Archiv - the whole September issue of Virchows Archiv #Springer #Virchows
Devoted to GU/kidney tumor #pathology

Many papers are freely accessible: https://t.co/vXgrKLlXE2

#PathTwitter #PathX #GUpath

[WC Faquin, MD, PhD @bfaquin]

Harvard and MGB pathology course this October 26-30!

[Miguel Reyes-Múgica @mreyesm]

#PediPath

[Springer Pathology @SpringerPath]

A study identifies high-grade renal tumors linked to FLCN mutations, characterized by aggressive features and varied growth patterns. The findings highlight the need for FLCN testing in cases resembling high-grade papillary RCC.

https://t.co/fhKcZmSmRi

[Janira Navarro @Janiranavarro]

WHAT'S NEW IN COLORECTAL TUMORS (WHO 6TH EDITION 2026)
Low-grade tubuloglandular adenocarcinoma

-Almost exclusively in IBD
-Well diff glands with no desmoplasia
-May be mistaken for non-invasive disease on biopsy

Dr. Srivastava GIPS pathcast https://t.co/mI21vtZVD8 #pathology #PathX

[Miruna Popescu, MD @MirunaPopescu13]

Excited to share our @Pathoutlines article on OGT-rearranged mesenchymal neoplasm has been published online. Grateful to everyone for their help/contribution!

Check it out
👇🏻👇🏻👇🏻👇🏻
https://t.co/2Pl14AtCqa

3 things to remember about OGT-rearranged mesenchymal neoplasm (also known as myoepthelioma-like hyalinizing epithelioid tumor, MHET):
💎 Well circumscribed, multinodular, composed of bland epithelioid to spindled cells set in a 2 toned stroma with myxochondroid (blue) and acellular hyalinized (pink) areas
💎 Signet ring-like cells with cytoplasmic processes engulfing extracellular hyaline globular material
💎 No IHC evidence of myoepithelial diff (➖ve for AE1/ AE3, SOX10, S100P, GFAP)
Consistently ➕ve for CD34

🌟Bonus info: Recurrent fusions of OGT and members of FOXO, most commonly FOXO3, FOXO1, FOXO4

#PathTwitter #BSTPath

[Ting Zhao, MD @TingZhaoPathdoc]

🚨Excited to share that our second spatial transcriptomics paper on GU tumors has been published! @LIjournal @TheUSCAP @MGBpathology
💠Spatial Transcriptomics of Micropapillary, Plasmacytoid, and Sarcomatoid Urothelial Carcinoma Reveals Distinct Molecular Landscapes
➡️Read here: https://t.co/16R0hruyG6

💡Our prior spatial transcriptomics study on prostate cancer:
https://t.co/B1RfO6gyNf

@IntSocUropath @GU_Path_Society
#Molpath #GUpath

[Guan-Nan Zhang ，张冠楠，MD, PhD @GuannanTiffany]

🧩 Urethral riddle

67-year-old man with a small urethral mass.

I confess, there is a trap. 😊

What is your diagnosis? What do you want to order?

#DxMindMap #UrethralPath #GUPath #PathTwitter @JHUpath

[Dr Geethanjali Gude @Gee2path]

@GIJamesMD Since its nuclear, MYB?

[Ting Zhao, MD @TingZhaoPathdoc]

🚨Check out our case report: Papillary-Predominant FLCN-Mutated Renal Epithelial Neoplasm in Birt-Hogg-Dubé Syndrome 🧬🧬

➡️https://t.co/yIS7i1XjXT

@MGBpathology @IJSPjournal
#MolPath #GUpath

[Rajal B Shah @rajalbshah]

Hot from Press of Advances in Anatomic Pathology! Based on the latest guidelines from joint GUPS/ISUP Expert Consultation, this highly illustrative guide on Intraductal Carcinoma of the prostate offers a unified framework to reduce variation and optimize patient management

[Liang Cheng, MD @LiangChengMD]

Delighted to share our article published this month in European Urology @EUplatinum (new Journal Impact Factor: 29).

Congratulations to our esteemed global multidisciplinary expert panel for making this landmark work possible. We hope these recommendations will improve communications and diagnostic reproducibility, streamline multidisciplinary patient care, and ultimately support earlier intervention and more personalized management of genitourinary diseases.

Full article: https://t.co/jPuanMN37T
@IntSocUropath

[Natasha Rekhtman MD PhD @natasharekhtman]

Just out in AJSP – a paper from our group describing a MAJOR new oddity.

Tumors that normally arise in the jaw from tooth🦷precursors (ameloblastoma) – but as lung primaries 🫁!

This was a neat collaboration b/w MSKCC, Mayo and UTSW where these cases were encountered independently, and we put our heads together with the help of original contributors and fellows to tackle this puzzle.

Time will tell if these are truly exceptional or have been underrecognized.

https://t.co/VVdG7wC7IG

@JLHornick @ENTpathology @MSKPathology @PulmPathSoc @yro854 @thoracicpath @Path_Matt @SansanoValero @AndreMo77438628

[Liang Cheng, MD @LiangChengMD]

Need an update on the molecular pathology of bladder cancer? I am delighted to share a comprehensive review article by Dr. Antonio Lopez-Beltran and colleagues, published in the 2026 Annual Review Issue of Histopathology @Histo_Journal @daniel_berney
🔗 Article: https://t.co/wPYmanaOxC

Advances in molecular classification, biomarker development, and personalized therapies are transforming the management of bladder cancer. The rapid expansion of therapeutic targets - together with ongoing clinical validation—underscores the essential role of pathologists, as pre-analytical and analytical considerations directly impact the approval, adoption, and optimal use of new cancer drugs. Integrating molecular and morphologic data into routine pathology reporting will be critical to support clinical decision-making and enable precision-based treatment.

Molecular classification remains a rapidly evolving research area with major potential to reshape clinical practice. The marked molecular and morphological heterogeneity of urothelial carcinoma presents challenges, but also offers opportunities to refine patient stratification and tailor therapeutic interventions. Emerging liquid-based biomarkers—including circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA)—show strong promise for detecting minimal residual disease, monitoring treatment response, and assessing disease dynamics in a minimally invasive manner.

For more GU-focused reviews, the full 2026 Histopathology Annual Review Issue (Special GU Edition) is available here:
🔗https://t.co/eBcHxVuroo

[Liang Cheng, MD @LiangChengMD]

Must-read! The latest issue of the American Journal of Surgical Pathology features several practice-changing guideline and consensus papers that will serve as essential references for pathologists, urologists, oncologists, and medical professionals interested in urologic malignancies. Big congratulations and sincere thanks to our outstanding expert consensus panelists for their phenomenal scholarship, leadership, and collaborative efforts in advancing the practice of urologic surgical pathology! More to Come with Working Group 3- 5  Recommendations  - Stay Tuned @IntSocUropath
-    Iczkowski KA et al. International Society of Urological Pathology Consensus on Cancer Precursor Lesions. Working Group 1: The Prostate. Am J Surg Pathol 2025;49:e33-45. PMID: 40545966  https://t.co/QrTvaJ2rxf
-    Downes MR et al. International Society of Urological Pathology Consensus Meeting 2024: Working Group 2 Preneoplastic and Precursor Lesions of the Urinary Bladder. Am J Surg Pathol2025;49:e46-57. PMID: 40590266
https://t.co/N2idLVrtYB
-    Shah RB et al. Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer. Am J Surg Pathol 2025; 49:e27-32. PMID: 40444986.   https://t.co/NvQy3FdH5P
-    Reis H et al. The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Urachal Neoplasms. Am J Surg Pathol 2025; 49:e18-26. PMID: 40471793 https://t.co/2fWjqaZVuK

Interested in urologic pathology/GU malignancies? Please join the International Society of Urological Pathology (ISUP) and connect with a global community of GU experts:
👉 https://t.co/PmTWyjwq6e

@JLHornick @AJSPjournal

[Human Pathology @Human_Pathology]

New in #HumPathol: Three Practice Updates in Non-Hodgkin Lymphoma for 2026. https://t.co/VORp8ynEDY #pathology #PathTwitter #PathX #hemepath

[Histopathology @Histo_Journal]

The OLGIMA system for gastric cancer risk assessment. A useful method based on the histological Sydney consensus - Delgado Guillena - Histopathology - Wiley Online Library #gipath https://t.co/cd114DjH13

[Rajal B Shah @rajalbshah]

Attention Pathologists: Proud to present unified practice recommendations on Intraductal Carcinoma of the Prostate! No more confusion or contradictory recommendations between 2 leading societies! Download your free copy https://t.co/1ayogQ3VQy

[ROHIT MEHRA @drmehrarohit]

@rovingatuscap presenting nuances of Gleason pattern 4 application in clinical practice #prostatecancer @UroOnc #SUO25

[Dr Geethanjali Gude @Gee2path]

@neuropathology Rosai dorfman disease